Verification evidence is still being completed.
PDF / print export
Cardior Pharmaceuticals GmbH
Hannover, Germany
- Verified lead
- Claudia Ulbrich
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Co-Founder
- 2026 technical specialization
- RNA-Targeting Cardiovascular Therapeutics, miRNA Modulation, and Heart Failure Clinical Development
- Review cycle
- 24 April 2026
- Full address
- Hollerithallee 20, 30419 Hannover, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- BioPharma Dive coverage quoting Cardior CEO Claudia Ulbrich on the Novo Nordisk deal.
- Editorial note
- Hannover RNA-targeting cardiovascular therapeutics company with named founder-CEO, a Phase 2 CDR132L heart-failure program, and wholly-owned Novo Nordisk subsidiary status after the 2024 acquisition.
RNA-Targeting Cardiovascular Therapeutics, miRNA Modulation, and Heart Failure Clinical Development
Public CEO disclosure via BioPharma Dive coverage, Bundeskartellamt clearance record, Hannover Handelsregister record HRB 214001
Hannover RNA-targeting cardiovascular therapeutics company with named founder-CEO, a Phase 2 CDR132L heart-failure program, and wholly-owned Novo Nordisk subsidiary status after the 2024 acquisition.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Hannover, Germany
Cardior Pharmaceuticals GmbH
RNA-Targeting Cardiovascular Therapeutics, miRNA Modulation, and Heart Failure Clinical Development · Clinical-stage drug development under Novo Nordisk umbrella
Hannover RNA-targeting cardiovascular therapeutics company with named founder-CEO, a Phase 2 CDR132L heart-failure program, and wholly-owned Novo Nordisk subsidiary status after the 2024 acquisition.
- Lead
- Claudia Ulbrich (verified ↗)
- Address
- Hollerithallee 20, 30419 Hannover, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage drug development under Novo Nordisk umbrella
- Capabilities
- RNA-Targeting Cardiovascular Drug Discovery · CDR132L miR-132 Antisense Program · Translational Cardiovascular Pipeline
- Founded
- 2016
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Claudia Ulbrich
Chief Executive Officer and Co-Founder
Full addressHollerithallee 20, 30419 Hannover, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Clinical-stage drug development under Novo Nordisk umbrella
Hannover, Germany. RNA-Targeting Cardiovascular Therapeutics, miRNA Modulation, and Heart Failure Clinical Development. Review completed on 24 Apr 2026.
BfArM and EMA within Novo Nordisk regulatory footprint
Public CEO disclosure via BioPharma Dive coverage, Bundeskartellamt clearance record, Hannover Handelsregister record HRB 214001
RNA-Targeting Cardiovascular Therapeutics, miRNA Modulation, and Heart Failure Clinical Development
Hannover RNA-targeting cardiovascular therapeutics company with named founder-CEO, a Phase 2 CDR132L heart-failure program, and wholly-owned Novo Nordisk subsidiary status after the 2024 acquisition.
Editorial note
Cardior is a Hannover Medical School spin-off advancing RNA-targeting cardiovascular drug discovery and became a wholly-owned Novo Nordisk subsidiary in Q2 2024 after Bundeskartellamt clearance on 18 April 2024.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
RNA-Targeting Cardiovascular Drug Discovery
CDR132L miR-132 Antisense Program
Translational Cardiovascular Pipeline
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
RNA therapeutics discovery workflow
Translational cardiovascular research
Integrated access to Novo Nordisk cardiovascular pipeline
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Cardior Pharmaceuticals GmbH located?
- Cardior Pharmaceuticals GmbH operates from Hollerithallee 20, 30419 Hannover, Germany, Hannover, Germany.
- Who runs Cardior Pharmaceuticals GmbH?
- Cardior Pharmaceuticals GmbH is led by Claudia Ulbrich, Chief Executive Officer and Co-Founder. Verified 24 Apr 2026.
- What does Cardior Pharmaceuticals GmbH do?
- Hannover RNA-targeting cardiovascular therapeutics company with named founder-CEO, a Phase 2 CDR132L heart-failure program, and wholly-owned Novo Nordisk subsidiary status after the 2024 acquisition. Core capabilities: RNA-Targeting Cardiovascular Drug Discovery, CDR132L miR-132 Antisense Program, Translational Cardiovascular Pipeline.
Editorial context
Related technical briefs
Briefs that name Hannover as a covered market or city.